Impact of HIV infection and HAART on serum lipids in men.

By S. Riddler, E. Smit, Stephen R. Cole, Rui Li, J. Chmiel, A. Dobs, F. Palella, B. Visscher, R. Evans, L. Kingsley. Journal of the American Medical Association (JAMA), 2003

693 citations recorded by the source corpus.

Subfields: Emergency Medicine, Endocrinology, Diabetes and Metabolism, Virology

View Paper: https://www.semanticscholar.org/paper/9d33cb5e3e27112e1974d7b2132606350ea2518f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Marja-Riitta Taskinen
2. I. Graham
3. Alberico L. Catapano
4. Rhian M. Touyz

Citations in the corpus

• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “PUFAs of the n-3 series have no hypocholesterolaemic effect; conversely, when they are used at high dosages (>3 g/day), the effect on LDL-C levels is either neutral or a slight increase [particularly with docosahexaenoic acid (DHA)] with a concomitant decrease of TGs. 165 A positive relationship exi”
• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “Human immunodeficiency disease (HIV)-infected patients typically have low TC, and LDL-C and high-density lipoprotein cholesterol (HDL-C) levels, as well as increased TG levels.(31,32) Antiretroviral treatment (ART) or highly active ART (when drugs are used in combination) causes marked increases in ”
• Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. (2007, background): “An increased rate of dyslipidemia has been well documented in smaller studies of HIV-infected populations, and may relate to effects of HIV as well as ARV therapy (18, 19).”